Hologic price target raised to $79 from $78 at UBS

UBS raised the firm’s price target on Hologic to $79 from $78 and keeps a Neutral rating on the shares. Execution on FY24 guidance is key given the challenging comps, continued work down of the elevated Breast Health backlog and expanding Panther utilization, the analyst tells investors in a research note.